Ana Cardio possibility of exercises at Licence a program in hEarth Fwrong from Helsinki
Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“Helsinn”), a fully integrated global biopharmaceutical company with a diverse pipeline of innovative oncology assets and a strong track record of commercial execution, and AnaCardio, a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, are delighted to announce that AnaCardio has exercised its licensing option with Helsinn for a program in heart failure, a condition associated with poor quality of life, poor prognosis and which remains a major medical need not satisfied.
Under the terms of the agreement, and upon payment of an undisclosed amount, AnaCardio exercised its option and obtained an exclusive license from Helsinn for the clinical development of the program in heart failure, with potential revenue sharing downstream during further licensing, sale or marketing. from the program.
Following the preclinical and clinical discovery of a new mode of action in cardiovascular and heart failure by Professor Lars Lund, founder of Anacardio and Professor of Cardiology at Karolinska Institutet and Karolinska University Hospital , Anacardio intends to initiate a proof-of-concept Phase II clinical trial, which is expected to begin in mid-2022.
Giorgio Calderari, CEO Helsinn Group: “As Helsinn continues to focus on its recently announced Fully Integrated Targeted Therapy (FITT) strategy, developing innovative actives in oncology, it is great to see one of our proprietary, non-essential programs making progress in an indication cardiovascular. Benefiting from our in-depth expertise and the comprehensive preclinical and phase I data we have generated, Professor Lund and AnaCardio are ideally placed to pursue the clinical development of this program in heart failure. We look forward to supporting AnaCardio in its efforts to develop a new treatment option for patients.”
patrick Stromberg, CEO of Ana Cardio: “We are honored to partner with such an experienced and successful company as Helsinn. This licensing agreement completes the transformation of AnaCardio into a fully operational clinical-stage development company, and underscores our commitment to the heart failure community. and to develop effective treatments for this underserved patient group.
Teacher. lund commented: “Heart failure is associated with poor quality of life and is among the most common causes of hospitalization and death. We are very pleased to have an innovative first-class treatment concept, with the potential to improve cardiac contractility, and therefore has the ultimate goal of improving symptoms and outcomes both in the immediate acute and long-term heart failure in chronic heart failure. cardiac arrest.”
About Helsinn Group
Helsinn is a fully integrated global biopharmaceutical company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients worldwide through a leadership position in supportive cancer care and an innovative pipeline of cancer therapies.
Helsinn is a third-generation family business that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. It operates a unique licensing business model with integrated drug development and manufacturing capabilities. Helsinn is commercially present in 190 countries either directly, with operational subsidiaries in the United States and China, or through its network of long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd.
The Helsinn Group plays an active and central role in promoting social transformation for people and the environment. Corporate social responsibility is at the heart of everything we do, which is reinforced in the company’s strategic plan by a commitment to sustainable growth.
To learn more about Helsinn Group, visit www.helsinn.com
AnaCardio AB is a privately held, clinical-stage Swedish biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded on the basis of groundbreaking research from the Karolinska Institutet showing an improvement in heart muscle contractility through a unique and differentiated mechanism. Its lead AC01 program is expected to enter phase II clinical development in heart failure patients in 2022.
You can find more information about AnaCardio at www.anacardio.com.
For more information:
Helsinn Group media contact:
Group Communications Manager
Tel: +41 (0) 91 985 21 21
Email: [email protected]
For more information, visit www.helsinn.com and follow us on Twitter and LinkedIn
Ana Cardio Contact:
Tel: +46 (0) 704 156 159
Email: [email protected]